Skip to content
MarketScale
‹ Back to IndustriesHealthcare

It’ll Take a Village to Deliver the Innovative, Less Invasive, Affordable Solutions to the Healthcare Market with Raja Abid

There’s no getting around the fact that the healthcare industry needs solutions to help solve its myriad challenges. A holistic approach to healthcare solutions is a pathway Raja Abid, Healthcare Economic Leader at Boston Scientific, believes can deliver innovative, less invasive, and affordable solutions to the healthcare market. Abid kicked off his career in med…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

There’s no getting around the fact that the healthcare industry needs solutions to help solve its myriad challenges. A holistic approach to healthcare solutions is a pathway Raja Abid, Healthcare Economic Leader at Boston Scientific, believes can deliver innovative, less invasive, and affordable solutions to the healthcare market.

Abid kicked off his career in med school. He discovered there were so many facets to healthcare he wanted to learn different sides of the market. Abid got his MBA in healthcare administration, which opened his eyes to the many possibilities for him to make a difference. Keeping an open mind is a trait Abid values, and it’s what guided him through his career and led him to Boston Scientific.

All areas within healthcare offer tremendous value and opportunities to create solutions, but the siloing that often accompanies these areas must dissipate to allow for better communication. “The only way you’re going to improve quality, value, and delivery of care, is when everybody starts talking to each other, builds care pathways that make sense, efficient, and highly effective,” Abid said. Still, Abid believes the next ten years in healthcare will focus on solving this challenge.

In Abid’s role with Boston Scientific, he provides economic support data, so healthcare organizations understand the financial impact of the devices they purchase. A device may seem like a significant spend, but long-term financial benefits and positive patient results generated from that device could be tremendous.

Seeing healthcare from the side of a device manufacturer, Abid knows that solutions come from partnerships. “Medical device companies come up with new products and technologies. We educate the physicians and the patients on their options because, as you can imagine, most patients go to a physician, and a physician’s going to do what they’ve been doing for the last fifteen to twenty years.” Educating the healthcare community on the latest innovations can make all the difference.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Who's Really Running Healthcare? (When Physicians No Longer Have a Voice) - Dr. Krishna Vedala

Who's Really Running Healthcare? (When Physicians No Longer Have a Voice) - Dr. Krishna Vedala

Physician burnout stems not just from workload but from loss of meaningful voice in healthcare organizations. Dr. Krishna Vedala discusses how primary care is mismanaged as a procedural business, how AI should free physicians from administrative work rather than replace them, and why physicians may need collective representation to restore trust between clinicians and administrators.

  • 01Physicians increasingly lack meaningful participation in organizational decisions, despite being closest to patients and responsible for care delivery.
  • 02Primary care requires complex, nuanced decision-making but is often managed with productivity expectations designed for procedural specialties, pushing work home and some physicians toward breaking point.
  • 03AI's highest value is reducing administrative burden and documentation so physicians have more time with patients, not replacing clinical judgment or human relationships.

Sep 8, 2026

MRI segmentation models can now label 80 structures, but deployment is the hard part

MRI segmentation models can now label 80 structures. TotalSegmentator MRI is an nnU-Net model that provides rapid segmentation of all major organs across all MRI sequences, according to Radiology Business. For health systems, deployment is the hard part.

  • 01The spread between 0.97 Dice on lungs and 0.54 on portal and splenic veins in MRSegmentator is the real operational story: enterprises need confidence flags and escalation paths, not a single headline score.
  • 02Hospitals planning radiation oncology and neuro volumetry programs can treat segmentation speedups as capacity gains only if downstream steps, contour review, dose planning inputs, and reporting templates, are standardized.

Sep 8, 2026

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512